PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF), the health sciences company developing preventative therapies, has confirmed its first peptide with promising preclinical potential as a non-addictive painkiller.
The Vancouver-based company shared the news in a positive update on Wednesday on its non-addictive analgesic dynorphin pain peptide program.
After shortlisting of a panel of peptides showing “promising cell-based activity” and “extended stability” in two distinct types of biological media, the program has identified its first peptide with clear "in vivo activity in a rat model” of inflammatory pain, PreveCeutical said in the statement.
The pre-clinical peptide has “demonstrated effectiveness in alleviating moderate inflammatory pain” after administration of a single dose, said the company. Researchers at PreveCeutical plan to test other shortlisted peptides from the panel for their analgesic activity in the in-vivo rat model.
This outcome highlights the “potential of appropriately designed, opioid-receptor selective peptides” in alleviating pain, said the company.
"This novel peptide has the potential for further development as a non-addictive analgesic drug candidate, based on the 'pre-clinical' animal studies that have been conducted so far," said Dr Mak Jawadekar who is the CEO of PreveCeutical Medical.
The Canadian health sciences company has five research and development programs, including gene therapy, its Sol-gel program for nose-to-brain delivery of medical compounds including cannabinoids, as well as non-addictive analgesic peptides as a replacement for morphine, fentanyl and oxycodone.
Contact the author Uttara Choudhury at [email protected]
Follow her on Twitter: @UttaraProactive